Clarity Capital Partners LLC Takes $29,000 Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)

Clarity Capital Partners LLC bought a new position in shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 11,500 shares of the company’s stock, valued at approximately $29,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of ELDN. Vanguard Group Inc. increased its stake in Eledon Pharmaceuticals by 39.4% during the first quarter. Vanguard Group Inc. now owns 969,121 shares of the company’s stock worth $1,996,000 after purchasing an additional 273,703 shares during the period. Nantahala Capital Management LLC acquired a new position in shares of Eledon Pharmaceuticals in the second quarter valued at approximately $1,584,000. Armistice Capital LLC increased its stake in Eledon Pharmaceuticals by 1.7% during the 2nd quarter. Armistice Capital LLC now owns 2,336,000 shares of the company’s stock worth $6,167,000 after buying an additional 39,000 shares during the period. Dimensional Fund Advisors LP acquired a new stake in Eledon Pharmaceuticals during the 2nd quarter worth approximately $80,000. Finally, Renaissance Technologies LLC boosted its position in Eledon Pharmaceuticals by 57.1% in the 2nd quarter. Renaissance Technologies LLC now owns 136,773 shares of the company’s stock valued at $361,000 after buying an additional 49,704 shares during the period. 56.77% of the stock is currently owned by hedge funds and other institutional investors.

Eledon Pharmaceuticals Stock Down 8.9 %

Eledon Pharmaceuticals stock opened at $4.83 on Tuesday. Eledon Pharmaceuticals, Inc. has a twelve month low of $1.07 and a twelve month high of $5.54. The stock’s fifty day simple moving average is $2.87 and its 200-day simple moving average is $2.72.

Eledon Pharmaceuticals (NASDAQ:ELDN) last issued its quarterly earnings results on Monday, August 19th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.01). On average, analysts predict that Eledon Pharmaceuticals, Inc. will post -1.52 earnings per share for the current fiscal year.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).